Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:729639rdf:typepubmed:Citationlld:pubmed
pubmed-article:729639lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:729639lifeskim:mentionsumls-concept:C1882598lld:lifeskim
pubmed-article:729639lifeskim:mentionsumls-concept:C0007412lld:lifeskim
pubmed-article:729639lifeskim:mentionsumls-concept:C0025741lld:lifeskim
pubmed-article:729639lifeskim:mentionsumls-concept:C0683928lld:lifeskim
pubmed-article:729639lifeskim:mentionsumls-concept:C0205178lld:lifeskim
pubmed-article:729639lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:729639lifeskim:mentionsumls-concept:C0205227lld:lifeskim
pubmed-article:729639pubmed:issue3-4lld:pubmed
pubmed-article:729639pubmed:dateCreated1979-3-24lld:pubmed
pubmed-article:729639pubmed:abstractTextAcute administration of alpha-methyldopa (200 mg kg-1 s.c.) produced a short-lived decrease in dopamine levels in 5 regions of the rat brain. Maximal dopamine depletion was 55% in the corpus striatum and over 75% in other regions and occurred 4--6 h after alpha-methyldopa injection; dopamine levels recovered within 12 h. Maximal noradrenaline depletion of over 80% occurred in all regions 4--24 h after alpha-methyldopa and after 24 h noradrenaline levels were still significantly reduced from control values. In these acute studies alpha-methyldopamine accumulated rapidly in amounts equal to or greater than the depleted dopamine in all regions, reaching a peak at 4 h. By contrast, alpha-methylnoradrenaline accumulated more slowly reaching a peak at 6--24 h and was never present in amounts greater than the depleted noradrenaline. Following chronic administration of alpha-methyldopa (40 mg kg-1 s.c., twice daily 5 days) there was a similar depletion of noradrenaline and dopamine to that seen in the acute studies. The depletion was associated with a much smaller accumulation of alpha-methyldopamine. The striking feature of these results, however, was the large accumulation of alpha-methylnoradrenaline in all brain regions. This probably reflects the slow turnover and resistance to degradation by monoamine oxidase of alpha-methylnoradrenaline.lld:pubmed
pubmed-article:729639pubmed:languageenglld:pubmed
pubmed-article:729639pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:729639pubmed:citationSubsetIMlld:pubmed
pubmed-article:729639pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:729639pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:729639pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:729639pubmed:statusMEDLINElld:pubmed
pubmed-article:729639pubmed:monthDeclld:pubmed
pubmed-article:729639pubmed:issn0014-2999lld:pubmed
pubmed-article:729639pubmed:authorpubmed-author:JarrottBBlld:pubmed
pubmed-article:729639pubmed:authorpubmed-author:ConwayE LELlld:pubmed
pubmed-article:729639pubmed:authorpubmed-author:LouisW JWJlld:pubmed
pubmed-article:729639pubmed:issnTypePrintlld:pubmed
pubmed-article:729639pubmed:day1lld:pubmed
pubmed-article:729639pubmed:volume52lld:pubmed
pubmed-article:729639pubmed:ownerNLMlld:pubmed
pubmed-article:729639pubmed:authorsCompleteYlld:pubmed
pubmed-article:729639pubmed:pagination271-80lld:pubmed
pubmed-article:729639pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:729639pubmed:meshHeadingpubmed-meshheading:729639-A...lld:pubmed
pubmed-article:729639pubmed:meshHeadingpubmed-meshheading:729639-R...lld:pubmed
pubmed-article:729639pubmed:meshHeadingpubmed-meshheading:729639-B...lld:pubmed
pubmed-article:729639pubmed:meshHeadingpubmed-meshheading:729639-M...lld:pubmed
pubmed-article:729639pubmed:meshHeadingpubmed-meshheading:729639-C...lld:pubmed
pubmed-article:729639pubmed:meshHeadingpubmed-meshheading:729639-M...lld:pubmed
pubmed-article:729639pubmed:meshHeadingpubmed-meshheading:729639-N...lld:pubmed
pubmed-article:729639pubmed:meshHeadingpubmed-meshheading:729639-T...lld:pubmed
pubmed-article:729639pubmed:meshHeadingpubmed-meshheading:729639-D...lld:pubmed
pubmed-article:729639pubmed:meshHeadingpubmed-meshheading:729639-M...lld:pubmed
pubmed-article:729639pubmed:meshHeadingpubmed-meshheading:729639-H...lld:pubmed
pubmed-article:729639pubmed:year1978lld:pubmed
pubmed-article:729639pubmed:articleTitleAcute and chronic administration of alpha-methyldopa: regional levels of endogenous and alpha-methylated catecholamines in rat brain.lld:pubmed
pubmed-article:729639pubmed:publicationTypeJournal Articlelld:pubmed